Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression

Figure 2

Representative pictures of double immunostaining with anti-aquaporin-3 (AQP3; green channel) and anti-aquaporin-2 (AQP2; red channel) antibodies in kidney sections from a control patient (left), a patient with severe COVID-19 (middle), and a patient with severe COVID-19 and sevoflurane-associated nephrogenic diabetes insipidus (right). Nuclei are stained with DAPI (4′,6-diamidino-2-phenylindole).